HS
MLYS icon

HighVista Strategies’s Mineralys Therapeutics MLYS Stock Holding History

HighVista Strategies’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Sell
46,778
-77,766
-62% -$2.28M 0.35% 95
2025
Q4 		$4.52M Sell
124,544
-85,285
-41% -$3.42M 1.16% 26
2025
Q3 		$7.96M Buy
209,829
+59,691
+40% +$1.29M 1.95% 8
2025
Q2 		$2.03M Buy
+150,138
New +$2.18M 0.75% 43

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

HighVista Strategies's MLYS Position: Q1 2026 in Review

HighVista Strategies reduced its Mineralys Therapeutics (MLYS) stake by 62% in Q1 2026, selling an estimated $2.28M and leaving 46,778 shares worth $1.27M. The position accounts for 0.35% of the portfolio, ranked #95.

HighVista Strategies first reported a position in MLYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $7.96M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • HighVista Strategies held 46,778 shares of Mineralys Therapeutics worth $1.27M as of Q1 2026.
  • HighVista Strategies sold 77,766 Mineralys Therapeutics shares in Q1 2026, an estimated $2.28M.
  • Mineralys Therapeutics made up 0.35% of HighVista Strategies's portfolio in Q1 2026, its #95 holding.
  • HighVista Strategies first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • HighVista Strategies's Mineralys Therapeutics position peaked at $7.96M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.